ACCEL Lite: ESC Congress 2021 Late Breaker: MASTER DAPT

This large, multicentre, randomized trial was conducted with patients at high risk for bleeding who had undergone biodegradable polymer sirolimus-eluting stent implantation to assess whether one month of dual antiplatelet therapy preserves the net and major adverse cardiovascular events. And if so, whether it mitigates major or nonmajor clinically relevant bleeding occurrences, compared with longer treatment durations.

In this episode, Prof Marco Valgimigli, MD, PhD, FESC and Poonam Velagapudi MD, MS discuss ESC Late Breaker: MASTER DAPT: dual antiplatelet therapy after coronary stenting in high bleeding risk patients.

Like what you hear? ACCEL Subscribers enjoy 20+ insider interviews like these every month, with CME/MOC credit and other exclusive benefits. Subscribe today for more, and check out what's new at

Clinical Topics: Acute Coronary Syndromes, Anticoagulation Management, Invasive Cardiovascular Angiography and Intervention, Prevention, Stable Ischemic Heart Disease, Atherosclerotic Disease (CAD/PAD), Anticoagulation Management and ACS, Interventions and ACS, Interventions and Coronary Artery Disease, Chronic Angina

Keywords: ACCELLite, ESC Congress, ESC21, Acute Coronary Syndrome, Anticoagulants, Coronary Artery Disease, Coronary Restenosis, Drug-Eluting Stents, Hemorrhage, Myocardial Infarction, Myocardial Ischemia, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Primary Prevention, Risk, Sirolimus, Stents, Stroke, Thrombosis

< Back to Listings